ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

The development of acquired resistance to small molecule tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) signaling has hindered their efficacy in treating non-small cell lung cancer (NSCLC) patients. Our previous study showed that constitutive activation of the 70...

Full description

Bibliographic Details
Main Authors:	Lei Zhao, Yifang Wang, Xin Sun, Xiujuan Zhang, Nicole Simone, Jun He
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	International Journal of Molecular Sciences
Subjects:	EGFR-TKI gefitinib S6K1 MTOR ELK1 resistance
Online Access:	https://www.mdpi.com/1422-0067/25/4/2382

Similar Items

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Gefitinib Results in Robust Host-Directed Immunity Against Salmonella Infection Through Proteo-Metabolomic Reprogramming
by: Srikanth Sadhu, et al.
Published: (2021-03-01)

Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancreatic Cancer Cells to Genistein
by: Tianyu Li, et al.
Published: (2021-09-01)

Tobacco extracts promote PD‐L1 expression and enhance malignant biological differences via mTOR in gefitinib‐resistant cell lines
by: Fengqi Xiao, et al.
Published: (2020-08-01)

Uncommon <i>EGFR</i> Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
by: Ilaria Attili, et al.
Published: (2022-01-01)

Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation
by: Yimeng Zhang, et al.
Published: (2024-04-01)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
by: Naoto Aiko, et al.
Published: (2018-10-01)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
by: Taiji Kuwata, et al.
Published: (2016-10-01)

The SETD8/ELK1/bach1 complex regulates hyperglycaemia-mediated EndMT in diabetic nephropathy
by: Xue Li, et al.
Published: (2022-03-01)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
by: Yanjun Huang, et al.
Published: (2018-07-01)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
by: Xiaomeng Wang, et al.
Published: (2019-11-01)

Case Report: Fading Elk Syndrome in a Herd of Captive Elk (Cervus elaphus) in the North American Midwest
by: Paola M. Boggiatto, et al.
Published: (2020-08-01)

Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro
by: Wei WEI, et al.
Published: (2009-01-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
by: Tung-Yung Huang, et al.
Published: (2020-08-01)

Commentary: Antidepressive effects of targeting ELK-1 signal transduction
by: Chang-Hoon Cho
Published: (2018-10-01)

High expression of RTEL1 predicates worse progression in gliomas and promotes tumorigenesis through JNK/ELK1 cascade
by: Guanjie Wang, et al.
Published: (2024-03-01)

ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis
by: Qiang Yan, et al.
Published: (2021-12-01)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
by: Ping Chen, et al.
Published: (2019-06-01)

HORNED ELKS IN THE TOM PETROGLYPHS
by: I. V. Kovtun, et al.
Published: (2014-11-01)

Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
by: Jin Zou, et al.
Published: (2022-07-01)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
by: Daisuke Hayakawa, et al.
Published: (2020-01-01)

Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets
by: Nan Wei, et al.
Published: (2020-08-01)

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis
by: Goncharenko-Khaider Nadzeya, et al.
Published: (2012-11-01)

Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer
by: Yuan-Chin Tsai, et al.
Published: (2018-02-01)

Road and highway undercrossings as potential critical linkages for California’s elk populations
by: Richard B. Lanman, et al.
Published: (2022-10-01)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
by: Peijun Cao, et al.
Published: (2022-03-01)

ELK4 Promotes Colorectal Cancer Progression by Activating the Neoangiogenic Factor LRG1 in a Noncanonical SP1/3‐Dependent Manner
by: Zhehui Zhu, et al.
Published: (2023-11-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)

ROSTRAL STYLE OF "FLYING" ELKS FROM TUTALSKAYA PISANITSA
by: I. V. Kovtun
Published: (2014-02-01)

A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer
by: Jia Huafeng, et al.
Published: (2018-04-01)

Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells
by: Shaojia Wang, et al.
Published: (2021-05-01)

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
by: Ju Lixia, et al.
Published: (2013-02-01)

GPX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1
by: Sitian Wei, et al.
Published: (2022-08-01)

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
by: Mayra Colardo, et al.
Published: (2021-05-01)

Habitat suitability assessment for tule elk in the San Francisco Bay and Monterey Bay areas
by: Thomas Connor, et al.
Published: (2023-12-01)

Glucose Homeostasis and Pancreatic Islet Size Are Regulated by the Transcription Factors Elk-1 and Egr-1 and the Protein Phosphatase Calcineurin
by: Gerald Thiel, et al.
Published: (2023-01-01)